Trial Profile
Influence of marker of insulin resistance upon HCV treatment responses to PEG Intron and Rebetol therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 21 Jul 2006 New trial record.